MediWound receives marketing authorization for NexoBrid in Russia

MediWound announced receipt of authorization from the Ministry of Health in Russia to market and distribute NexoBrid for the removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. Genfa Medica, MediWound’s exclusive distribution partner in Russia, received the marketing authorization and intends to launch NexoBrid in Russia in the first half of 2019. This regulatory approval builds upon NexoBrid’s marketing authorization from the European Medicines Agency for the same indication and again validates MediWound’s strategy of using the EMA approved registration file for seeking approval in different international markets around the globe.
https://thefly.com/landingPageNews.php?id=2785747